@article{ATM1330,
author = {Preet Paul Singh and Siddharth Singh},
title = {Statins - the Holy Grail for cancer?},
journal = {Annals of Translational Medicine},
volume = {1},
number = {1},
year = {2013},
keywords = {},
abstract = {Statins or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been used for primary and secondary prevention of cardiovascular diseases and currently are the most commonly prescribed drug class in the world. Besides cholesterol reduction, pre-clinical studies have shown that statins may exert antineoplastic effects, through both HMG-CoA reductase-dependent and HMG-CoA reductase-independent pathways. By competitive inhibition of HMG-CoA reductase, statins prevent post-translational prenylation of the Ras/Rho superfamily, which are important mediators of cell growth, differentiation and survival (1).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/1330}
}